Compare PICS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PICS | NVAX |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 1996 |
| Metric | PICS | NVAX |
|---|---|---|
| Price | $11.08 | $9.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $23.00 | $11.33 |
| AVG Volume (30 Days) | 622.9K | ★ 4.5M |
| Earning Date | 03-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $135.00 | N/A |
| Revenue Next Year | $39.69 | N/A |
| P/E Ratio | $29.44 | ★ $3.71 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $10.30 | $5.01 |
| 52 Week High | $18.49 | $11.85 |
| Indicator | PICS | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 30.68 | 45.71 |
| Support Level | N/A | $9.14 |
| Resistance Level | $15.83 | $10.42 |
| Average True Range (ATR) | 1.21 | 0.55 |
| MACD | -0.36 | -0.16 |
| Stochastic Oscillator | 15.08 | 3.97 |
PicS NV is a digital payments company. The company operates a peer-to-peer (P2P) transfer platform that enables individuals to send money via mobile devices. It provides digital wallets, instant payments (Pix), P2P transfers, credit cards, loans, investments, insurance, and SMB payment solutions. The company has four reportable segments: Consumer Banking, Small and Medium-Sized Businesses, Audiences and Ecosystem Integration, and Institutional. The majority of the company's revenue is derived from the Consumer Banking segment, which generates revenue from various transaction activities occurring in the digital wallet, such as Pix, peer-to-peer (P2P) transfers, and bill payments.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.